277 related articles for article (PubMed ID: 25036587)
1. Olanzapine-induced triglyceride and aminotransferase elevations without weight gain or hyperglycemia normalized after switching to aripiprazole.
Pawelczyk T; Pawelczyk A; Rabe-Jablonska J
J Psychiatr Pract; 2014 Jul; 20(4):301-7. PubMed ID: 25036587
[TBL] [Abstract][Full Text] [Related]
2. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
3. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials.
Hoffmann VP; Case M; Stauffer VL; Jacobson JG; Conley RR
J Clin Psychopharmacol; 2010 Dec; 30(6):656-60. PubMed ID: 21105275
[TBL] [Abstract][Full Text] [Related]
5. Aripirazole-olanzapine combination for treatment of schizophrenia.
Duggal HS
Can J Psychiatry; 2004 Feb; 49(2):151. PubMed ID: 15065751
[No Abstract] [Full Text] [Related]
6. Olanzapine-induced elevation of serum triglyceride levels in a normal weight patient with schizophrenia.
Nagamine T
Intern Med; 2008; 47(3):181-2. PubMed ID: 18239330
[TBL] [Abstract][Full Text] [Related]
7. Profound hypertriglyceridemia and weight gain in the first week following initiation of olanzapine: a case report with implications for lipid monitoring guidelines.
Kimmel RJ; Levy MR
Psychosomatics; 2013; 54(4):392-4. PubMed ID: 23261075
[No Abstract] [Full Text] [Related]
8. Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
Schuster JP; Raucher-Chéné D; Lemogne C; Rouillon F; Gasquet I; Leguay D; Gierski F; Azorin JM; Limosin F
J Clin Psychopharmacol; 2012 Oct; 32(5):672-7. PubMed ID: 22926602
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole for the management of olanzapine-induced weight gain.
Englisch S; Weinbrenner A; Inta D; Zink M
Pharmacopsychiatry; 2009 Jul; 42(4):166-7. PubMed ID: 19585397
[No Abstract] [Full Text] [Related]
11. Switching and combining antipsychotics.
Correll CU
CNS Spectr; 2010 Apr; 15(4 Suppl 6):8-11. PubMed ID: 21141654
[No Abstract] [Full Text] [Related]
12. What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?
Deng C; Chen J; Hu C; Huang XF
J Clin Psychopharmacol; 2010 Aug; 30(4):480-1. PubMed ID: 20631576
[No Abstract] [Full Text] [Related]
13. Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.
Chavez B; Poveda RA
Ann Pharmacother; 2006 Dec; 40(12):2265-8. PubMed ID: 17119107
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
Kasteng F; Eriksson J; Sennfält K; Lindgren P
Acta Psychiatr Scand; 2011 Sep; 124(3):214-25. PubMed ID: 21609324
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
Fleischhacker WW; McQuade RD; Marcus RN; Archibald D; Swanink R; Carson WH
Biol Psychiatry; 2009 Mar; 65(6):510-7. PubMed ID: 18986646
[TBL] [Abstract][Full Text] [Related]
17. Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
Citrome L; Weiden PJ; Alva G; Glick ID; Jackson R; Mattingly G; Kianifard F; Meng X; Winseck A
Clin Schizophr Relat Psychoses; 2015 Jan; 8(4):183-95. PubMed ID: 25367165
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.
Hirose T; Uwahodo Y; Yamada S; Miwa T; Kikuchi T; Kitagawa H; Burris KD; Altar CA; Nabeshima T
J Psychopharmacol; 2004 Sep; 18(3):375-83. PubMed ID: 15358981
[TBL] [Abstract][Full Text] [Related]
19. Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine.
Marshall PB; Mellman TA; Nguyen SX
Am J Psychiatry; 2008 Nov; 165(11):1488-9. PubMed ID: 18981078
[No Abstract] [Full Text] [Related]
20. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
